Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Kodiak Sciences Inc

KOD
Current price
2.71 USD +0.33 USD (+13.87%)
Last closed 2.38 USD
Company kodiak.com
ISIN US50015M1099
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 121 539 952 USD
Yield for 12 month +26.64 %
1Y
3Y
5Y
10Y
15Y
KOD
21.11.2021 - 28.11.2021

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as well as Phase III clinical study for the treatment of diabetic macular edema, naïve macular edema due to retinal vein occlusion, and non-proliferative diabetic retinopathy. The company's preclinical stage product candidate includes KSI-501, a bispecific conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for retinal inflammatory conditions. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California. Address: 1200 Page Mill Road, Palo Alto, CA, United States, 94304

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

2.75 USD

P/E ratio

Dividend Yield

Current Year

Last Year

Current Quarter

Last Quarter

Current Year

-25 947 000 USD

Last Year

-11 001 000 USD

Current Quarter

-6 681 000 USD

Last Quarter

-6 646 000 USD

Key Figures KOD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -192 783 008 USD
Operating Margin TTM
PE Ratio
Return On Assets TTM -26.72 %
PEG Ratio
Return On Equity TTM -71.5 %
Wall Street Target Price 2.75 USD
Revenue TTM
Book Value 4.09 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY
Dividend Yield
Gross Profit TTM
Earnings per share -3.77 USD
Diluted Eps TTM -3.77 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics KOD

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History KOD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation KOD

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue
Price Sales TTM
Enterprise Value EBITDA -0.1181
Price Book MRQ 0.5654

Financials KOD

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators KOD

For 52 weeks

1.37 USD 7.77 USD
50 Day MA 2.67 USD
Shares Short Prior Month 1 857 887
200 Day MA 3.6 USD
Short Ratio 7.06
Shares Short 1 740 774
Short Percent 5.37 %